ATLASLycia Therapeutics, Inc. IPO (LYCA)
The data feed lists Lycia Therapeutics, Inc. for NASDAQ with a start date of Oct 23, 2026, status "Priced", and an offer price of $18.00 per the final prospectus (424B4). First-day change from open to close: +5.1%.
Updated November 4, 2026 · Source: IPO calendar data feed (EODHD) and the company's SEC filings
What the company does
Lycia Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. The company leverages its proprietary LYTAC (Lysosomal Targeting Chimera) platform and has pipeline candidates including LCA-0061 and LCA-0062 (IgE-targeted, for allergic diseases including food allergy) and LCA-0321 (for Graves' disease), all in Phase 1 clinical trials. The company was incorporated in Delaware on October 24, 2019 and is headquartered in South San Francisco, California.
The offer
- Offer price
- $18.00
- Shares offered
- 17,640,000
- Gross proceeds
- $317,520,000
- Net proceeds to the company
- $290.7M ($335.0M with full option)
- Shares outstanding after the offering
- 55,034,559
- Lead underwriters
- Jefferies, TD Cowen, Evercore ISI, Guggenheim Securities
- Lock-up
- 180 days
Use of proceeds
The company intends to use approximately $80.0 million to advance the clinical development of LCA-0061 substantially through its planned Phase 2 clinical trial, approximately $70.0 million to advance the clinical development of LCA-0062 substantially through its planned Phase 2 clinical trial, approximately $90.0 million to advance the clinical development of LCA-0321 substantially through its planned Phase 2 clinical trial, and the remainder for research pipeline, other research and development activities, working capital and other general corporate purposes.
- LCA-0061 Phase 2 clinical development$80.0M
- LCA-0062 Phase 2 clinical development$70.0M
- LCA-0321 Phase 2 clinical development$90.0M
Financials
| US$ thousands | FY2024 | FY2025 | 6M 2025 | 6M 2026 |
|---|---|---|---|---|
| Revenue | 14,936 | 6,741 | 2,306 | 0 |
| Net income (loss) | -26,503 | -36,460 | -25,624 | -19,196 |
| Cash and marketable securities | — | — | — | 148,091 |
| Total assets | — | — | — | 156,760 |
Key risks
No approved products. The company has a limited operating history, has not completed any clinical trials and has no products approved for commercial sale, which may make it difficult for investors to evaluate its business, likelihood of success and viability.
Significant operating losses. The company has incurred significant operating losses since inception, has not generated any revenue from product sales, and expects to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
Need for additional capital. Even if this offering is successful, the company will require substantial additional capital to finance its operations and achieve its goals, and if unable to raise capital when needed, may be forced to delay, reduce or eliminate its research or development programs.
Platform dependency risk. The company is substantially dependent on the success of its LYTAC platform to advance clinical development of LCA-0061, LCA-0062 and LCA-0321, and any setback to the platform or core technology could adversely affect all therapeutic candidates and its ability to build out its pipeline.
Uncertain clinical outcomes. Drug development is a lengthy and expensive process with inherently uncertain clinical testing outcomes, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.
Timeline
- Oct 5, 2026 · Registration statement filed (S-1)
- Oct 20, 2026 · Amendment (S-1/A)
- Oct 23, 2026 · Final prospectus (price set) (424B4) View filing
- Oct 26, 2026 · Current report (8-K)
Sources on SEC EDGAR
Facts come from the company's SEC filings; calendar data from EODHD. Information only, not investment advice. Profile updated Nov 4, 2026.
Calendar data
| Status in feed | Priced |
|---|---|
| Start date | Oct 23, 2026 |
| Exchange | NASDAQ |
| Shares offered | 17,640,000 |
| First-day change (open to close) | +5.08% |
| First-day open | $28.55 |
| First-day close | $30 |
| Filing date | Oct 23, 2026 |
| Last amended | Oct 23, 2026 |
Follow this IPO in ATLAS PRO
IPO alerts are part of ATLAS PRO. Create your account to follow LYCA and get one email when it starts trading.
Create an accountFrequently asked questions
What does Lycia Therapeutics, Inc. do?
Lycia Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. The company leverages its proprietary LYTAC (Lysosomal Targeting Chimera) platform and has pipeline candidates including LCA-0061 and LCA-0062 (IgE-targeted, for allergic diseases including food allergy) and LCA-0321 (for Graves' disease), all in Phase 1 clinical trials. The company was incorporated in Delaware on October 24, 2019 and is headquartered in South San Francisco, California.
How much is the Lycia Therapeutics, Inc. IPO raising?
The final prospectus sets a price of $18.00 per share for 17,640,000 shares, or $317,520,000 before expenses and discounts.
Who are the underwriters of the Lycia Therapeutics, Inc. IPO?
Jefferies, TD Cowen, Evercore ISI, Guggenheim Securities.
When is the Lycia Therapeutics, Inc. IPO?
The data feed lists a start date of Oct 23, 2026 with status "Priced".
What is the Lycia Therapeutics, Inc. IPO price range?
According to the final prospectus (424B4), the offer price is $18.00 per share.
How is the first-day change measured?
On the first trading day (Oct 23, 2026) the stock moved +5.08% from its open ($28.55) to its close ($30), from daily price data. This is not the change from the IPO offer price.
What does "Priced" mean?
The feed reports the offering as priced. The start date is the first trading day.
Can I get an email when this IPO starts trading?
Yes. ATLAS PRO accounts can follow an IPO inside the platform and get one email when it starts trading. This is information, not investment advice.
Educational information, not investment advice. Disclaimer